Bibliografisk note

Funding Information:
Disclosure: Dr Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis, Bristol-Meyers Squibb, UCB, Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. Dr Skov has been a paid speaker for Pfizer, AbbVie, Eli Lilly, Novartis, and LEO Pharma; has been a consultant or served on advisory boards with Pfizer, AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, and Sanofi; has served as an investigator for Pfizer, AbbVie, Eli Lilly, Novartis, Amgen, Regeneron, and LEO Pharma; and received research and educational grants from Pfizer, AbbVie, Novartis, Sanofi, Janssen Cilag, and Leo Pharma. The authors do not have equity in pharmaceutical companies. Funding sources: None.

Funding Information:
Disclosure: Dr Egeberg has received research funding from Pfizer , Eli Lilly , the Danish National Psoriasis Foundation , and the Kgl Hofbundtmager Aage Bang Foundation and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis, Bristol-Meyers Squibb, UCB, Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. Dr Skov has been a paid speaker for Pfizer, AbbVie, Eli Lilly, Novartis, and LEO Pharma; has been a consultant or served on advisory boards with Pfizer, AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, and Sanofi; has served as an investigator for Pfizer, AbbVie, Eli Lilly, Novartis, Amgen, Regeneron, and LEO Pharma; and received research and educational grants from Pfizer , AbbVie , Novartis , Sanofi , Janssen Cilag , and Leo Pharma . The authors do not have equity in pharmaceutical companies.